# Zafrira Avnur

> Zafrira Avnur is a Series A investor at Quark Venture backing Life Science and Therapeutics. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Quark Venture](https://shizune.co/investors/profile/quark-venture)
- Location: Cupertino, United States
- Total investments: 3
- Last investment: Mar 2021
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/zafrira-avnur-180604200

Zafrira Avnur is a Series A investor at Quark Venture in Cupertino focused on Life Science and Therapeutics. Zafrira Avnur - Chief Scientific Officer @ Quark Venture

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Life Science | 2 | 67% |
| Therapeutics | 2 | 67% |
| Biotechnology | 2 | 67% |
| Health Care | 1 | 33% |
| Information Technology | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 67% |
| Series D | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 67% |
| Spain | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CalciMedica | CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $21M | Series D | Mar 11, 2021 |  |
| EnClear Therapies | EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will targetimproving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). | $10M | Series A | Feb 19, 2020 |  |
| ABAC Therapeutics | ABAC Therapeutics is aimed at seeking first-in-class drugs for precision treatment of MDR Gram-negative infections. While potent pathogen-specific antibacterial activity is essential, we believe that it is necessary to incorporate early other pharmaceutical properties, such as suitable pharmacokinetics and toxicological characteristics, to maximizethe chance of success in clinical development. | $17.6M | Series A | Feb 15, 2018 |  |

3 of 3 investments shown.

## Co-investors
- [Presight Capital](https://shizune.co/investors/profile/presight-capital) — VC Fund, 2 deals together
- [20/20 HealthCare Partners](https://shizune.co/investors/profile/20-20-healthcare-partners) — VC Fund, 1 deal together
- [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures) — VC Fund, 1 deal together
- [Bioverge](https://shizune.co/investors/profile/bioverge) — VC Fund, 1 deal together
- [Criteria Venture Tech](https://shizune.co/investors/profile/caixa-capital) — VC Fund, 1 deal together
- [Debiopharm Innovation Fund](https://shizune.co/investors/profile/debiopharm-innovation-fund) — VC Fund, 1 deal together

## About Quark Venture

VC Fund · Vancouver, Canada

Established in 2015, Quark Venture Inc. is a venture capital investment firm, headquartered in Vancouver, Canada, and is focused on equity financing of innovative biotechnology and health sciences companies with breakthrough technology platforms and projects.

4 contacts available at Quark Venture.

| Name | Title | Profile |
| --- | --- | --- |
| Karimah Es Sabar | Chief Executive Officer & Partner | https://shizune.co/investors/profile/karimah-es-sabar |
| Neena Kadaba | Director, Science | https://shizune.co/investors/profile/neena-kadaba |
| Zafrira Avnur | Chief Scientific Officer | https://shizune.co/investors/profile/zafrira-avnur |
| Jesson Chen | Co-Founder, Chairman & Partner | https://shizune.co/investors/profile/jesson-chen |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Zafrira Avnur invest in?

Zafrira Avnur invests primarily in Life Science, Therapeutics and Biotechnology startups, most often at Series A and Series D stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Zafrira Avnur last invest?

The most recent investment recorded for Zafrira Avnur closed in Mar 2021. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co